VERA - Vera Therapeutics, Inc.
IEX Last Trade
42.37
-0.100 -0.236%
Share volume: 8,906
Last Updated: Thu 26 Dec 2024 08:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$42.47
-0.10
-0.24%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.92%
1 Month
-11.67%
3 Months
-8.19%
6 Months
24.32%
1 Year
162.33%
2 Year
110.65%
Key data
Stock price
$42.37
DAY RANGE
$41.34 - $43.09
52 WEEK RANGE
$15.35 - $51.61
52 WEEK CHANGE
$162.49
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Marshall W. Fordyce
Region: US
Website: veratx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: veratx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vera Therapeutics, Inc. focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for immunoglobulin A nephropathy.
Recent news